Hines RN - Search Results

1

Novel CYP2C9 promoter variants and assessment of their impact on gene expression.

Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN. Kramer MA, et al. Among authors: hines rn. Mol Pharmacol. 2008 Jun;73(6):1751-60. doi: 10.1124/mol.107.044149. Epub 2008 Feb 29. Mol Pharmacol. 2008. PMID: 18310303 Free PMC article.

2

Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6).

Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG. Hines RN, et al. J Pharmacol Exp Ther. 2003 Sep;306(3):1210-8. doi: 10.1124/jpet.103.053686. Epub 2003 Jun 26. J Pharmacol Exp Ther. 2003. PMID: 12829732

3

Developmental expression of human hepatic CYP2C9 and CYP2C19.

Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Koukouritaki SB, et al. Among authors: hines rn. J Pharmacol Exp Ther. 2004 Mar;308(3):965-74. doi: 10.1124/jpet.103.060137. Epub 2003 Nov 21. J Pharmacol Exp Ther. 2004. PMID: 14634042

4

Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.

Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN. Koukouritaki SB, et al. Among authors: hines rn. Mol Pharmacol. 2005 Aug;68(2):383-92. doi: 10.1124/mol.105.012062. Epub 2005 Apr 27. Mol Pharmacol. 2005. PMID: 15858076

5

Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression.

Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Koukouritaki SB, et al. Among authors: hines rn. Pediatr Res. 2002 Feb;51(2):236-43. doi: 10.1203/00006450-200202000-00018. Pediatr Res. 2002. PMID: 11809920

6

Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.

Zheng YM, Henne KR, Charmley P, Kim RB, McCarver DG, Cabacungan ET, Hines RN, Rettie AE. Zheng YM, et al. Among authors: hines rn. Toxicol Appl Pharmacol. 2003 Jan 15;186(2):119-26. doi: 10.1016/s0041-008x(02)00028-5. Toxicol Appl Pharmacol. 2003. PMID: 12639503

7

CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians.

Rettie AE, Tai G, Veenstra DL, Farin FM, Srinouanprachan S, Lin YS, Thummel KE, Hines RN. Rettie AE, et al. Among authors: hines rn. Blood. 2003 Apr 1;101(7):2896-7. doi: 10.1182/blood-2002-11-3452. Blood. 2003. PMID: 12642346 Free article. No abstract available.

8

Identification and functional analysis of a novel human CYP2E1 far upstream enhancer.

Shadley JD, Divakaran K, Munson K, Hines RN, Douglas K, McCarver DG. Shadley JD, et al. Among authors: hines rn. Mol Pharmacol. 2007 Jun;71(6):1630-9. doi: 10.1124/mol.106.031302. Epub 2007 Mar 12. Mol Pharmacol. 2007. PMID: 17353354

9

Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.

Krueger SK, Siddens LK, Henderson MC, Andreasen EA, Tanguay RL, Pereira CB, Cabacungan ET, Hines RN, Ardlie KG, Williams DE. Krueger SK, et al. Among authors: hines rn. Pharmacogenet Genomics. 2005 Apr;15(4):245-56. doi: 10.1097/01213011-200504000-00008. Pharmacogenet Genomics. 2005. PMID: 15864117 Free PMC article.

10

Regulation of flavin-containing monooxygenase 1 expression by ying yang 1 and hepatic nuclear factors 1 and 4.

Luo Z, Hines RN. Luo Z, et al. Among authors: hines rn. Mol Pharmacol. 2001 Dec;60(6):1421-30. doi: 10.1124/mol.60.6.1421. Mol Pharmacol. 2001. PMID: 11723251

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters